Matthew Strobeck, Director at Accelerate Diagnostics, Inc (AXDX), bought 8,000 shares at $19.00 ($152K) on 2017-01-09, disclosed to the SEC on 2017-01-10.
Open-market purchase of $152k AXDX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| AZYO | BUY | 2023-02-13 | $398K | — | Filing → |
| BDSX | BUY | 2022-11-21 | $5.4M | — | Filing → |
| BDSX | BUY | 2022-04-11 | $2.0M | — | Filing → |